[go: up one dir, main page]

MX2019010541A - Compuestos de imidazo-piperidina fusionada como inhibidores de jak. - Google Patents

Compuestos de imidazo-piperidina fusionada como inhibidores de jak.

Info

Publication number
MX2019010541A
MX2019010541A MX2019010541A MX2019010541A MX2019010541A MX 2019010541 A MX2019010541 A MX 2019010541A MX 2019010541 A MX2019010541 A MX 2019010541A MX 2019010541 A MX2019010541 A MX 2019010541A MX 2019010541 A MX2019010541 A MX 2019010541A
Authority
MX
Mexico
Prior art keywords
imidazo
compounds
piperidine compounds
jak inhibitors
compounds fused
Prior art date
Application number
MX2019010541A
Other languages
English (en)
Other versions
MX388750B (es
Inventor
R Fatheree Paul
Smith Cameron
d e sullivan Steven
Jean Van Orden Lori
E L Brandt Gary
A Kleinschek Melanie
D Crater Glenn
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2019010541A publication Critical patent/MX2019010541A/es
Publication of MX388750B publication Critical patent/MX388750B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los compuestos de fórmula (I): (ver fórmula I) donde las variables se definen en la memoria descriptiva, o una sal farmacéuticamente aceptable del mismo, son útiles como inhibidores de la quinasa JAK. También se proveen composiciones farmacéuticas que comprenden tales compuestos, métodos para usar tales compuestos para tratar procesos y enfermedades respiratorias, e intermediarios útiles para preparar tales compuestos.
MX2019010541A 2017-03-09 2018-03-08 Compuestos de imidazo-piperidina fusionada como inhibidores de jak. MX388750B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469073P 2017-03-09 2017-03-09
PCT/US2018/021492 WO2018165395A1 (en) 2017-03-09 2018-03-08 Fused imidazo-piperidine jak inhibitors

Publications (2)

Publication Number Publication Date
MX2019010541A true MX2019010541A (es) 2019-10-21
MX388750B MX388750B (es) 2025-03-20

Family

ID=61683956

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010541A MX388750B (es) 2017-03-09 2018-03-08 Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
MX2019010539A MX388749B (es) 2017-03-09 2018-03-08 Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019010539A MX388749B (es) 2017-03-09 2018-03-08 Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak.

Country Status (20)

Country Link
US (10) US10196393B2 (es)
EP (2) EP3592742B1 (es)
JP (2) JP6974487B2 (es)
KR (2) KR102533646B1 (es)
CN (2) CN110382498B (es)
AR (2) AR111242A1 (es)
AU (2) AU2018231035B2 (es)
BR (2) BR112019018649A2 (es)
CA (1) CA2997772A1 (es)
DK (1) DK3592742T3 (es)
EA (2) EA037748B1 (es)
ES (1) ES2882186T3 (es)
IL (2) IL268689B2 (es)
MX (2) MX388750B (es)
PH (2) PH12019501941A1 (es)
PT (1) PT3592742T (es)
SG (2) SG11201907840RA (es)
TW (2) TWI754019B (es)
WO (2) WO2018165392A1 (es)
ZA (2) ZA201905585B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA123633C2 (uk) 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
US10556901B2 (en) * 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
TWI754019B (zh) * 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CA3059785A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
WO2020051135A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
BR112021004052A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas de dimetil-amino azetidina como inibidores de jak
JP7383696B2 (ja) 2018-09-04 2023-11-20 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としての５員～７員の複素環アミド
CA3113667A1 (en) 2018-10-29 2020-05-07 Theravance Biopharma R&D Ip, Llc 2-azabicyclo hexane compound as jak inhibitor
EP3932919B1 (en) 2019-02-25 2024-06-26 Henan Medinno Pharmaceutical Technology Co., Ltd. Jak inhibitor compound and use thereof
PH12021552130A1 (en) 2019-03-05 2022-08-31 Incyte Corp Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
CN114901659A (zh) * 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
CN113121509B (zh) * 2019-12-30 2024-04-26 河南迈英诺医药科技有限公司 Jak抑制剂化合物及其用途
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
EP3944859A1 (en) * 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022178215A1 (en) * 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
CA3223194A1 (en) * 2021-06-25 2022-12-29 Theravance Biopharma R&D Ip, Llc Imidazolo indazole compounds as jak inhibitors
EP4450492A4 (en) * 2021-12-17 2025-10-15 Daewoong Pharmaceutical Co Ltd NEW ACID ADDITION SALT AND CRYSTALLINE FORM OF (2R,3S)-2-(3-(4,5-DICHLORO-1H-BENZO[D]IMIDAZOL-1-YL)PROPYL)PIPERIDIN-3-OL
CN117658852A (zh) * 2023-11-15 2024-03-08 西北工业大学 取代苯氧乙酰肼类化合物及其制备方法和作为stat3的抗炎抑制剂的应用
WO2025157904A1 (en) * 2024-01-24 2025-07-31 Kiox Pharmaceuticals Aps Inhalable formulations of ruxolitinib, methods of manufacture and uses thereof
CN118903009B (zh) * 2024-10-11 2025-01-21 江苏长泰药业股份有限公司 一种调节呼吸道微生态的丙酮酸钠气雾剂及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
HUE035612T2 (en) 2009-12-21 2018-05-28 Samumed Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
EP2338888A1 (en) * 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
WO2013060636A1 (en) 2011-10-25 2013-05-02 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3318565B1 (en) 2013-12-05 2021-04-14 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
CR20160525A (es) 2014-05-14 2016-12-20 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
US10556901B2 (en) 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
ES2864035T3 (es) 2015-11-03 2021-10-13 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus
UA123633C2 (uk) 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
TWI754019B (zh) * 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
SG11201909376TA (en) 2017-05-01 2019-11-28 Theravance Biopharma R&D Ip Llc Crystalline forms of a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CA3059785A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
JP7383696B2 (ja) 2018-09-04 2023-11-20 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としての５員～７員の複素環アミド
BR112021004052A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas de dimetil-amino azetidina como inibidores de jak
WO2020051135A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof

Also Published As

Publication number Publication date
TW201840560A (zh) 2018-11-16
US11453668B2 (en) 2022-09-27
PH12019501985A1 (en) 2020-10-05
AR111241A1 (es) 2019-06-19
MX2019010539A (es) 2019-10-21
CN110382498B (zh) 2022-07-12
MX388750B (es) 2025-03-20
JP2020510015A (ja) 2020-04-02
KR20190127796A (ko) 2019-11-13
EA037748B1 (ru) 2021-05-18
US20200181141A1 (en) 2020-06-11
IL268689A (en) 2019-10-31
US10208040B2 (en) 2019-02-19
US11878977B2 (en) 2024-01-23
CA2997772A1 (en) 2018-09-09
KR20190127798A (ko) 2019-11-13
US20210269436A1 (en) 2021-09-02
AU2018231032A1 (en) 2019-09-05
US20200216447A1 (en) 2020-07-09
US11254669B2 (en) 2022-02-22
AU2018231035A1 (en) 2019-09-05
KR102533646B1 (ko) 2023-05-17
US20180258087A1 (en) 2018-09-13
AR111242A1 (es) 2019-06-19
ZA201905585B (en) 2020-05-27
JP2020510010A (ja) 2020-04-02
US20190127371A1 (en) 2019-05-02
US10196393B2 (en) 2019-02-05
AU2018231032B2 (en) 2021-08-19
US10519153B2 (en) 2019-12-31
BR112019018648A2 (pt) 2020-06-16
KR102526764B1 (ko) 2023-04-27
MX388749B (es) 2025-03-11
TWI779016B (zh) 2022-10-01
US20180258088A1 (en) 2018-09-13
IL268689B (en) 2022-10-01
TWI754019B (zh) 2022-02-01
ZA201905618B (en) 2021-05-26
IL268679B (en) 2021-10-31
EP3592743A1 (en) 2020-01-15
US10392386B2 (en) 2019-08-27
EP3592742B1 (en) 2021-05-19
NZ756823A (en) 2021-04-30
US20230063643A1 (en) 2023-03-02
ES2882186T3 (es) 2021-12-01
SG11201907840RA (en) 2019-09-27
IL268689B2 (en) 2023-02-01
US20190119275A1 (en) 2019-04-25
EA037261B1 (ru) 2021-03-01
IL268679A (en) 2019-10-31
EA201992128A1 (ru) 2020-01-29
US10550118B2 (en) 2020-02-04
JP6974487B2 (ja) 2021-12-01
AU2018231035B2 (en) 2021-09-09
EA201992126A1 (ru) 2020-02-05
US11667637B2 (en) 2023-06-06
CN110461839B (zh) 2022-08-23
WO2018165392A1 (en) 2018-09-13
PH12019501941A1 (en) 2020-07-06
US20190337945A1 (en) 2019-11-07
CN110382498A (zh) 2019-10-25
WO2018165395A1 (en) 2018-09-13
PT3592742T (pt) 2021-07-30
US10954237B2 (en) 2021-03-23
TW201837037A (zh) 2018-10-16
SG11201907544VA (en) 2019-09-27
BR112019018649A2 (pt) 2020-04-07
DK3592742T3 (da) 2021-08-09
AU2018231032A8 (en) 2019-10-17
EP3592742A1 (en) 2020-01-15
JP7134990B2 (ja) 2022-09-12
CN110461839A (zh) 2019-11-15
US20220289737A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
MX2019010541A (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
CO2020001469A2 (es) Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
DOP2017000034A (es) Compuestos de imidazopiridazina
ECSP18003372A (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
CR20160528A (es) Compuestos y composiciones para inducir condrogénesis
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
MX2014005342A (es) Inhibidores del virus de la hepatitis c.
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
UY36124A (es) Derivados de carboxamida
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.